Vertex Amend its Collaboration with CRISPR Therapeutics for Development and Commercialization of CTX001 in SCD and Beta Thalassemia
Shots: CRISPR to receive $900M up front with an additional $200M milestone upon the regulatory approval of CTX001. Vertex will responsible for the global development, […]